World Sleep 2022 | Current and upcoming clinical trials in iRBD

Aleksander Videnovic, MD, Massachusetts General Hospital, Harvard Medical School, Boston, MA, illustrates the state of clinical research in isolated REM sleep behavior disorder (iRBD). When talking about clinical trials in iRBD, it is essential to distinguish between those looking at the symptomatic treatment of iRBD and those centered on disease-modifying therapies (DMTs). Over the past years, there have been several updates on clinical trials focusing on the symptomatic treatment of the disease, including the recent confirmation of melatonin and clonazepam as effective first-line therapies. Dr Videnovic predicts a shift in future trial design from traditional symptom-focused trials to disease modification-based approaches. This interview took place during the World Sleep Congress 2022 in Rome, Italy.